Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

JE, Gallant; E, DeJesus; JR, Arribas; AL, Pozniak; B, Gazzard; RE, Campo; B, Lu; D, McColl; S, Chuck; J, Enejosa; JJ, Toole; AK, Cheng

doi:10.1056/nejmoa051871

Public

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Shared by NobleBlocks on Jan 1, 2006 • 12:00 AM UTC

Authors:

Gallant JE

DeJesus E

Arribas JR

Abstract

Background Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere.Methods We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had ...

Discussions